Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.

[1]  D. Gaudet,et al.  Evinacumab for Homozygous Familial Hypercholesterolemia. , 2020, The New England journal of medicine.

[2]  E. Stroes,et al.  The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? , 2020, Current opinion in lipidology.

[3]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[4]  W. Sasiela,et al.  Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia , 2019, Circulation.

[5]  H. Griffiths,et al.  Simvastatin reduces circulating oxysterol levels in men with hypercholesterolaemia , 2018, Redox biology.

[6]  D. Gaudet,et al.  ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. , 2017, The New England journal of medicine.

[7]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[8]  Richard G. Lee,et al.  Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides , 2017, The New England journal of medicine.

[9]  J. Danesh,et al.  ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. , 2017, Journal of the American College of Cardiology.

[10]  S. Kersten,et al.  Regulation of lipid metabolism by angiopoietin-like proteins , 2016, Current opinion in lipidology.

[11]  D. Gudbjartsson,et al.  Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease , 2016, Nature Genetics.

[12]  P. Fischer-Posovszky,et al.  Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin. , 2015, The Journal of clinical endocrinology and metabolism.

[13]  S. Kathiresan,et al.  Mutations in STAP1 Are Associated With Autosomal Dominant Hypercholesterolemia , 2014, Circulation research.

[14]  H. Jang,et al.  Pravastatin activates the expression of farnesoid X receptor and liver X receptor alpha in Hep3B cells. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[15]  G. Labbadia,et al.  Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization. , 2012, The Journal of clinical endocrinology and metabolism.

[16]  F. Blanco-Vaca,et al.  Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[17]  S. Kathiresan,et al.  Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[18]  G. Franceschini,et al.  Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3 , 2012, Circulation. Cardiovascular genetics.

[19]  P. Juvan,et al.  The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action , 2011, Pharmacogenetics and genomics.

[20]  M. Trip,et al.  Assessment of Carotid Atherosclerosis in Normocholesterolemic Individuals With Proven Mutations in the Low-Density Lipoprotein Receptor or Apolipoprotein B Genes , 2011, Circulation. Cardiovascular genetics.

[21]  M. Eriksson,et al.  Effects of high‐dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism , 2011, Journal of internal medicine.

[22]  Jonathan C. Cohen,et al.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. , 2010, The New England journal of medicine.

[23]  Albert K Groen,et al.  The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design. , 2010, Progress in lipid research.

[24]  Paul R Reid,et al.  Discovery of tertiary sulfonamides as potent liver X receptor antagonists. , 2010, Journal of medicinal chemistry.

[25]  T. Miida,et al.  Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events , 2010, Current opinion in lipidology.

[26]  Eric Boerwinkle,et al.  Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. , 2008, The Journal of clinical investigation.

[27]  Andrew J. Brown,et al.  Statins Inhibit Synthesis of an Oxysterol Ligand for the Liver X Receptor in Human Macrophages With Consequences for Cholesterol Flux , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Theresa Zhang,et al.  Regulation of the angiopoietin-like protein 3 gene by LXR Published, JLR Papers in Press, October 16, 2002. DOI 10.1194/jlr.M200367-JLR200 , 2003, Journal of Lipid Research.

[29]  H. Mabuchi,et al.  Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. , 2002, Journal of medicinal chemistry.

[30]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[31]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[32]  Timothy M. Willson,et al.  Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway* , 1997, The Journal of Biological Chemistry.

[33]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.